Author(s):
Magnani, Diogo M. ; Silveira, Cassia G. T. ; Rosen, Brandon C. ; Ricciardi, Michael J. ; Pedre?o-Lopez, N?ria ; Gutman, Martin J. ; Bailey, Varian K. ; Maxwell, Helen S. ; Domingues, Aline ; Gonzalez-Nieto, Lucas ; Avelino-Silva, Vivian I. ; Trindade, Mateus ; Nogueira, Juliana ; Oliveira, Consuelo Silva de ; Maestri, Alvino ; Felix, Alvina Clara ; Levi, Jos? Eduardo ; Nogueira, Mauricio L. ; Martins, Mauricio A. ; Martinez-Navio, Jos? M. ; Fuchs, Sebastian P. ; Whitehead, Stephen S. ; Burton, Dennis R ; Desrosiers, Ronald C. ; Kallas, Esper G. ; Watkins, David I.
Date: 2017
Origin: Oasisbr
Subject(s): Zika virus; Infec??o pelo Zika virus / sangue; Infec??o pelo Zika virus / imunologia; Infec??o pelo Zika virus / virologia; Anticorpos Neutralizantes / gen?tica; Anticorpos Neutralizantes / imunologia; Anticorpos Antivirais / gen?tica; Anticorpos Antivirais / imunologia; Anticorpos Monoclonais; Imunoglobulina G; Sequ?ncia de Amino?cidos; Epitopos Imunodominantes - imunologia; Muta??o em Linhagem Germinativa; Citometria de Fluxo - m?todos; Ensaio de Imunoadsor??o Enzim?tica / m?todos; Rea??o em Cadeia da Polimerase Via Transcriptase Reversa / m?todos; Testes de Neutraliza??o / m?todos
Description
University of Miami. Department of Pathology. Miami, FL, USA.
University of S?o Paulo. School of Medicine. Division of Clinical Immunology and Allergy. S?o Paulo, SP, Brazil.
University of Miami. Department of Pathology. Miami, FL, USA.
University of Miami. Department of Pathology. Miami, FL, USA.
University of Miami. Department of Pathology. Miami, FL, USA.
University of Miami. Department of Pathology. Miami, FL, USA.
University of Miami. Department of Pathology. Miami, FL, USA.
University of Miami. Department of Pathology. Miami, FL, USA.
University of Miami. Department of Pathology. Miami, FL, USA.
University of Miami. Department of Pathology. Miami, FL, USA.
Hospital S?rio-Liban?s. S?o Paulo, SP, Brazil.
Hospital S?rio-Liban?s. S?o Paulo, SP, Brazil / University of S?o Paulo. School of Medicine. Neurology Department. S?o Paulo, SP, Brazil.
Instituto Adolfo Lutz. S?o Paulo, SP, Brazil.
Minist?rio da Sa?de. Secretaria de Vigil?ncia em Sa?de. Instituto Evandro Chagas. Bel?m, PA, Brasil.
University of S?o Paulo. School of Medicine. Division of Clinical Immunology and Allergy. S?o Paulo, SP, Brazil.
Universidade de S?o Paulo. Instituto de Medicina Tropical de S?o Paulo. Faculdade de Medicina. Departamento de Mol?stias Infecciosas e Parasit?rias. S?o Paulo, SP, Brazil.
Universidade de S?o Paulo. Instituto de Medicina Tropical de S?o Paulo. Faculdade de Medicina. Departamento de Mol?stias Infecciosas e Parasit?rias. S?o Paulo, SP, Brazil.
Faculdade de Medicina de S?o Jos? do Rio Preto. Departamento de Doen?as Dermatol?gicas, Infecciosas e Parasit?rias. Laborat?rio de Pesquisas em Virologia. S?o Jos? do Rio Preto, SP, Brazil.
University of Miami. Department of Pathology. Miami, FL, USA.
University of Miami. Department of Pathology. Miami, FL, USA.
University of Miami. Department of Pathology. Miami, FL, USA.
National Institutes of Health. National Institute of Allergy and Infectious Diseases. Laboratory of Infectious Diseases. Bethesda, MD, USA.
The Scripps Research Institute. Department of Immunology and Microbiology. La Jolla, CA, USA / Massachusetts Institute of Technology and Harvard University. The Ragon Institute of Massachusetts General Hospital. Cambridge, MA, USA.
University of Miami. Department of Pathology. Miami, FL, USA.
University of S?o Paulo. School of Medicine. Division of Clinical Immunology and Allergy. S?o Paulo, SP, Brazil.
University of Miami. Department of Pathology. Miami, FL, USA.
The isolation of neutralizing monoclonal antibodies (nmAbs) against the Zika virus (ZIKV) might lead to novel preventative strategies for infections in at-risk individuals, primarily pregnant women. Here we describe the characterization of human mAbs from the plasmablasts of an acutely infected patient. One of the 18 mAbs had the unusual feature of binding to and neutralizing ZIKV despite not appearing to have been diversified by affinity maturation. This mAb neutralized ZIKV (Neut50 ~ 2 ?g/ml) but did not react with any of the four dengue virus serotypes. Except for the expected junctional diversity created by the joining of the V-(D)-J genes, there was no deviation from immunoglobulin germline genes. This is a rare example of a human mAb with neutralizing activity in the absence of detectable somatic hypermutation. Importantly, binding of this mAb to ZIKV was specifically inhibited by human plasma from ZIKV-exposed individuals, suggesting that it may be of value in a diagnostic setting.
